AU2290099A - Agent capable of modulating a glycosphingolipid-associated activity thus affecting an immune disorder - Google Patents

Agent capable of modulating a glycosphingolipid-associated activity thus affecting an immune disorder Download PDF

Info

Publication number
AU2290099A
AU2290099A AU22900/99A AU2290099A AU2290099A AU 2290099 A AU2290099 A AU 2290099A AU 22900/99 A AU22900/99 A AU 22900/99A AU 2290099 A AU2290099 A AU 2290099A AU 2290099 A AU2290099 A AU 2290099A
Authority
AU
Australia
Prior art keywords
agent
glycosphingolipid
associated activity
modulating
immune disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22900/99A
Inventor
Timothy Raymond Hirst
Neil Andrew Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bristol
Original Assignee
University of Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bristol filed Critical University of Bristol
Publication of AU2290099A publication Critical patent/AU2290099A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G01N2405/10—Glycosphingolipids, e.g. cerebrosides, gangliosides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

WO 99/38530 PCT/GB99/00290 1 AGENT CAPABLE OF MODULATING A GLYCOSPHINGOLIPID-ASSOCIATED ACTIVITY THUS AFFECTING AN IMMUNE DISORDER The present invention relates to a medicament. 5 In particular, the present invention relates to a medicament useful in the treatment of immune disorders. In particular, these disorders include inflammatory conditions, autoimmune diseases, allergic conditions, the treatment of cancers, including human leukaemias of a T cell origin and as agents in the prevention of human transplantation rejection and graft versus host disease (GVHD). 10 More in particular, in one aspect the present invention relates to an immunomodulatory agent. More in particular, the present invention relates to such an agent optionally co 15 administered with a specific antigen for use in the treatment of mammalian particularly human immune disorders. These disorders include inflammatory conditions, autoimmune diseases, allergic conditions, the treatment of cancers, including human leukaemias of a T cell origin and as agents in the prevention of human transplantation rejection and graft versus host disease (GVHD). 20 Autoimmunity is the term used to describe the mechanism by which the body generates an immune response to self-antigens. It has been disclosed in the art that agents which have GM-1 binding activity, or which have an effect on GM-1 mediated intracellular signalling events but no GM-1 binding activity, are useful as therapeutic 25 agents for, inter alia, autoimmune diseases. WO95/10301 disclosed agents which consisted of a mucosa-binding molecule linked to a specific tolerogen. However, in WO97/02045 we disclosed that in fact linkage between a GM-1 binding agent and the tolerogen was not required. Particular examples of GM-1 binding agents provided in WO97/02045 were cholera toxin (Ctx), the B subunit of cholera toxin (CtxB), the 30 E.coli heat labile toxin (Etx) and the B subunit of the E.coli heat labile toxin (EtxB).
WO 99/38530 PCT/GB99/00290 2 The term "allergy or hypersensitivity" is used to describe an adaptive immune response which occurs in an exaggerated or inappropriate form. Allergic or hypersensitivity reactions are the result of normally beneficial immune responses acting inappropriately to foreign antigens (usually environmental macromolecules) and 5 sometimes cause inflammatory reactions and tissue damage. In these situations, a normally harmless environmental stimulus, called an "allergen", triggers an immune response which upon re-exposure, is re-activated to generate pathological damage. Allergies or hypersensitivities are distinguished into four types of reactions. The first three are antibody-mediated, the fourth is mediated mainly by T cells and 10 macrophages. In Type I Immediate Hypersensitivity/Atopic Allergy, the principal immune response to the allergen involves the production of IgE antibodies. Such disorders are by far the most prevalent in humans and are seen as principal targets for new therapeutic 15 approaches. Although these diseases are not exclusively IgE mediated, IgE binds to cells within the tissues such as mast cells and basophils and the cross-linking of IgE on the cells surfaces by allergen invokes the release of many inflammatory mediators. Typical examples of such diseases include asthma, allergic cough, allergic rhinitis and 20 conjunctivitis, atopic eczema and dermatitis, urticaria, hives, insect bite allergy, dietary and certain drug allergies. In many cases, the particular allergens are known. By way of example, the principal allergen in asthma is DerP1 from house dust mite but other triggers of asthma such as pet dander antigens also exist. 25 Type II or antibody dependent cytotoxic hypersensitivity occurs when antibodies of a different type, usually IgG and IgM, binds to either self antigen or foreign antigen on cells and leads to phagocytosis, killer cell activity or complement mediated lysis. These types of allergies are relatively unusual but can include some allergies to drugs.
WO 99/38530 PCT/GB99/00290 3 Type III hypersensitivity develops when immune complexes are formed in large quantites or cannot be cleared adequately by the reticuloendothelial system. The immune complexes usually result from the deposition of antibody, usually IgM or IgG, allergen complexes at these sites. In normal circumstances, antibody binds to allergen 5 and is cleared by a variety of tissue cells. However, a number of factors may influence the persistence of the immune complexes and where they remain in the blood for prolonged periods, they can lodge and establish inflammation in the kidneys, skin (where they cause rashes) and joints (where they can cause a type of arthritis other than rheumatoid arthritis). 10 Type IV or delayed type hypersensitivity (DTH) does not involve antibody but instead the prolonged activation of T lymphocytes. These T cells are capable of secreting soluble factors causing tissue damage and enhancing the recruitment and activation of other cell types to the tissues. Incoming cells themselves contribute to the 15 inflammation and tissue damage. DTH is most seriously manifested when antigens (for example those associated with mycobacteria tuberculosis) are trapped in a macrophage and cannot be cleared. T cells are then stimulated to elaborate cytokines which mediate a range of inflammatory responses. DTH reactions are less common than Type I reactions but are seen in graft rejection and allergic contact dermatitis 20 which is generally manifested as a contact sensitivity (allergy usually involving skin rash) to environmental "contact allergens" such as heavy metals. Researchers have shown that a state of immunological unresponsiveness, also known as "immunological or oral tolerance", can be induced by the oral administration of 25 dietary protein antigens (Weiner, HL, Immunol Today 1997 18: 335-343; Sun et al 1994 ibid). The inhalation of antigens can also induce a state of specific immunological unresponsiveness or "nasal tolerance". Thus, systemic immunological tolerance can be induced when antigen is administered at mucosal sites (such as orally or nasally). WO 95/01301 discloses an immunological tolerance-inducing agent 30 comprising a mucosa-binding agent linked to a specific tolerogen. WO95/10301 also WO 99/38530 PCT/GB99/00290 4 includes mention of the treatment of allergy using a mucosa binding agent coupled to an allergen. Other researchers such as Tamura et al (1997 Vaccine 15: 225-229) have taken directly the protocol of WO 95/10301 and tested its efficacy in preventing allergy in a murine model of Type I allergy. They reported a significant lowering of 5 IgE levels which are a strong predictor of efficacy and they cite data, following administration of EtxB coupled to ovalbumin (the results were not included), which shows that EtxB was not effective once IgE levels are established. It has also been shown that orally administered Ctx and Etx can act on several humoral and cellular immune responses not only at the gastrointestinal tract, but also in distant mucosal 10 effector sites such as the respiratory tract. These data suggest that these mucosal adjuvants have a potential use in oral immunisation strategies to improve the local immune responses in remote mucosal tissues, in accordance with the concept of a common mucosal immune system (Bienenstock J 1974 The physiology of the local immune system and the gastrointestinal tract. In: Progress in Immunology II, vol 4: 15 clinical aspects, I.L. Brent, J.Holborrow, Eds. Amsterdam, North Holland, ppl97-207; Ruedl et al 1996 ibid; Umesaki 1992 ibid; Czerkinsky and Holmgren (1994 Cell Mol Biol 40: 37-44). The induction of immunological tolerance may include a number of different 20 mechanisms which may be summarised as follows: (i) a process whereby antigen reactive cells are removed through triggering them to commit suicide (apoptosis); 25 (ii) an induction of anergy or the long term inactivation of the antigen reactive cells; (iii) immune deviation of the antigen reactive cells away from the production of pathological responses; 30 WO 99/38530 PCT/GB99/00290 5 (iv) suppression of the antigen reactive cells or their regulation by specific factors or regulatory cells In the treatment of allergy, it is possible that the treatment of any of these mechanisms 5 may be useful. However, while the deletion of antigen reactive cells and/or the induction of anergy are useful strategies once the precise allergens are known, invoking these mechanims will usually silence only those cells which respond to the allergen which was given in the treatment regime. On the other hand, the implementation of immune deviation or suppression strategies has the advantage of 10 potential regulation of responses to antigens which are involved in the condition but were not part of the treatment. This phenomenon, known as "bystander suppression" allows the "spread" of tolerance to other antigens (such as allergens) in the target tissues through the possible secretion of non-antigen specific suppressor molecules in that tissue as a result of the interaction between the antigen specific cells and the 15 specific immunising antigen. In this way, as long as at least one of the antigens involved in the disorder is known, the condition may be treated even if there are other antigens implicated as well. Thus, the goal of a good treatment is the induction of a specific immune deviation or suppression. 20 Oral administration of antigens - such as allergens and autoantigens - has long been recognised as a method to prevent peripheral T cell responses and, in the case of autoantigens, has also been shown to prevent or delay the onset of several experimental autoimmune diseases including experimental allergic encephalomyelitis (EAE). Major problems recognised with such strategies are that it usually requires 25 feeding of large, if not massive, doses of autoantigens and it is generally less efficient in an immune as opposed to a naive host. The latter problem has limited the therapeutic potential of this strategy. However, it has now been shown by Sun et al (1994 Proc Natl Acad Sci 91: 10795-10799) that oral administration of minute amounts of prototype particulate and soluble protein antigens conjugated to cholera 30 toxin B subunit (CtxB), the nontoxic receptor-binding moiety of cholera toxin, can WO 99/38530 PCT/GB99/00290 6 readily induce tolerance in the peripheral T-cell compartment and is effective not only in naive but also in systemically sensitised animals. In addition, oral administration of minute amounts of an autoantigen, myelin basic protein (MBP) coupled to CtxB can prevent EAE in Lewis rats (Sun et al 1996 Proc Natl Acad Sci 93: 7196-7201). Other 5 researchers have also shown that feeding even a single dose of minute amounts (microgram) of antigens conjugated to the receptor binding nontoxic B subunit moiety of cholera toxin (CtxB) can markedly suppress systemic T cell mediated inflammatory reactions in naive as well as in experimental animals (Bergerot et al 1997 Proc Natl Acad Sci 94: 4610-4614). 10 Nashar and co-workers (Proc Natl Acad Sci 1996 93: 223-226; Int Immunol 1996 8: 731-736; Immunol 1997 91: 572-578) have demonstrated that the administration of EtxB and other homologues can modulate the immune response away from the production of Thl cytokines such as IFNy and interleukin 2 (IL-2) and towards the secretion of Th2 cytokines such as IL-4, IL-10 and IL-13. IFNy is the classical Thl 15 cytokine, IL-4 is the classical Th2 cytokine. This "immune deviation" is the basis of the disclosure in WO 97/02045. Earlier, we surprisingly found that agents having GM1 binding activity exert immunomodulatory effects useful in the treatment of allergic conditions and/or 20 hypersensitivity conditions (UK patent application No. 9800487.2). GM1 is a member of family of ganglioside receptors comprising sialic acid containing glycolipids (also called glycosphingolipids) which are formed by a hydrophobic portion, the ceramide and a hydrophilic part, that is the oligosaccharide chain. Within 25 cells, gangliosides are usually associated with plasma membranes, where they can act as receptors for a variety of molecules and have been shown to take part in cell-to-cell interaction and in signal transduction. Glycosphingolipids, other than GM1 gangliosides, are also capable of acting as plasma 30 membrane receptors.
WO 99/38530 PCT/GB99/00290 7 One member of this glycosphingolipid family which acts as a plasma membrane receptor is globotriaosylceramide, (Gb3), which is optionally represented as Gal cl-4Gal P31-4Glc 31-1 Cer 5 or Gal cl-4Gal P 1-4Glc-Cer 10 Gb3 mediates the internalisation of a family of E. coli derived toxins called verotoxins (VT), into susceptible cells by capping and receptor mediated endocytosis (RME) (Khine and Lingwood 1994 J Cell Physiol 161: 319-332). The action of the verotoxins (VT) in causing human vascular disease is dependent on the specific recognition of receptors on target endothelial cells (Nyholm et al 1996 Chem Biol 3: 263-275). Gb3 15 has been shown to be the most effective receptor for VT-1 in vitro and to be a functional plasma membrane receptor which mediates cytopathology for most sensitive cells (Boyd et al 1994 Eur J Biochem 223: 873-878). E. coli verotoxin has been characterized as having an "A" subunit of approximately 20 31,000 daltons and five "B" subunits each having an approximate molecular weight of 5,500 daltons. The A subunit possesses the biological activity of the toxin which is involved in inhibiting protein synthesis, whereas the B subunits are presumed to mediate specific binding and receptor-mediated uptake of the toxin. 25 The verotoxins are closely related to Shiga toxin and have been widely referred to as Shiga-like toxins (SLTs) as they mediate the same enterotoxic, cytotoxic, and neurotoxic effects of Shiga toxin, produced by the Shigella dysenteriae type 1. It has been shown that the antigenically distinct Shiga like toxins (SLTs) SLT-1 and SLT-II use Gb3 as functional receptors (Samuel et al 1990 Infect Immun 58: 611-618) 30 whereas the SLT II variants may use different receptors.
WO 99/38530 PCT/GB99/00290 8 The B subunits of verotoxins, VT1 and VT2 demonstrate terminal Gal cc 1-4 Gal dependent binding. The binding B oligomers of SLTI, SLTII and SLTIIvh recognize host cell glycolipid receptors containing at minimum the disaccharide subunit acGal(1-4)3Gal at the non-reducing terminus. SLTIIvp has been shown to bind to the 5 receptors containing this subunit but not necessarily at the non-reducing end (Samuel, J. E., et al Infect Immun (1990) 58:611-618; Boyd, B., et al Nephron (1989) 51:207-210; DeGrandis, S., et al J Biol Chem (1989) 264:12520-12525; Waddell, T., et al Biochem Biophys Res Chem (1988) 152:674-679; Lingwood, C. A., et al J Biol Chem (1987) 262:8834-8839; Waddell, T., et al Proc Nat1 Acad Sci USA (1990) 10 87:7898-7901; Cohen, A., et al J Biol Chem (1987) 262:17088-17091; Jacewicz, M., et al J. Exp Med (1986) 163:1391-1404; Lindberg, A. A., et al J Biol Chem (1987) 262:1779-1785). The carbohydrate recognition domain, also known as the P (k) trisaccharide, 15 of the Gb3 receptor for SLT-1 (St Hilaire et al 1994 Biochem 33: 14452-14463) is represented as methyl 4-O-(4-O-alpha-D-galactopyranosyl)-4-O-beta-D-glucopyranoside} 20 The terms "VT producing E coli (VTEC)" (Lingwood 1996 Trends Microbiol 4: 147 153) or "Shiga like toxin producing E coli (SLT-EC)" (Newburg et al 1993 J Infect Dis 168: 476-479) are widely used and interchangeable. Recently, a new unified nomenclature for the verotoxin, Shiga-like toxin and Shiga toxin family was proposed with the designation Stx being used for the entire family. The nomenclature Vtx shall 25 be used throughout the text of the present invention. Although workers know that the Gb3 receptor acts as a functional receptor for verotoxins, the possibility that receptor binding modulates the immune response has not yet been explored. 30 WO 99/38530 PCT/GB99/00290 9 The present invention now seeks to provide new ways of treating disorders such as allergic conditions or hypersensitivity conditions, autoimmune and inflammatory diseases, cancers such as human leukaemias of a T cell origin, transplantation rejection and graft versus host disease (GVHD), all collectively called "immune disorders". 5 According to a first aspect of the present invention, there is provided the use of an agent in the manufacture of a medicament to affect an immune disorder; wherein the agent is capable of modulating a glycosphingolipid associated activity; and wherein the modulation of the glycosphingolipid associated activity affects an immune 10 disorder. According to a second aspect of the present invention, there is provided the use of an agent in the manufacture of a medicament to affect an immune disorder; wherein the agent is capable of modulating a globotriaosylceramide (Gb3) associated activity; and 15 wherein the modulation of the Gb3 associated activity affects an immune disorder. Preferably, the agent is capable in vivo of modulating lymphocyte populations. Preferably, the agent is capable of acting as a vaccine adjuvant. 20 Preferably, the agent is capable of promoting the antigenicity of a protein. According to a fourth aspect of the present invention, there is provided an assay method for identifying an agent according to the present invention capable of affecting 25 an immune disorder; wherein the assay method comprises: (a) contacting an agent with a glycosphingolipid; (b) determining whether the agent modulates a glycosphingolipid associated activity; such that the modulation of the glycosphingolipid associated activity is indicative that the agent may be capable of affecting an immune disorder.
WO 99/38530 PCT/GB99/00290 10 According to a fifth aspect of the present invention, there is provided an assay method according to the present invention wherein the assay is an assay to screen for an agent useful in the prevention and/or treatment of an immune disorder. 5 According to a sixth aspect of the present invention, there is provided a process comprising the steps of: (a) performing the assay according to the present invention; (b) identifying one or more agents capable of modulating a glycosphingolipid associated activity; and (c) preparing a quantity of those one or more agents. 10 According to a seventh aspect of the present invention, there is provided a process comprising the steps of: (a) performing the assay according to the present invention; (b) identifying one or more agents capable of modulating a glycosphingolipid associated activity; and (c) preparing a pharmaceutical composition comprising one or more identified agents. 15 According to an eighth aspect of the present invention, there is provided a process comprising the steps of: (a) performing the assay according to the present invention; (b) identifying one or more agents capable of modulating a glycosphingolipid associated activity; and (c) modifying one or more identified agents capable of modulating a 20 glycosphingolipid associated activity; and (d) preparing a pharmaceutical composition comprising those one or more modified agents. According to a ninth aspect of the present invention, there is provided an agent identified by the process of the present invention. 25 Preferably the agent identified had not previously been known to affect an immune disorder through modulation of a glycosphingolipid associated activity. According to a tenth aspect of the present invention, there is provided a method of 30 affecting an immune disorder with one or more agents; wherein the agent is capable of WO 99/38530 PCT/GB99/00290 11 modulating a glycosphingolipid associated activity in an in vitro assay method; and wherein the in vitro assay method is the assay method defined in the present invention. Preferably there is provided a method of affecting in vivo an immune disorder with one 5 or more agents; wherein the agent is capable of modulating a glycosphingolipid associated activity in an in vitro assay method; and wherein the in vitro assay method is the assay method defined in the present invention. According to a eleventh aspect of the present invention, there is provided an agent 10 according to the present invention for use as a pharmaceutical. According to a twelfth aspect of the present invention, there is provided the use of an agent according to the present invention in the manufacture of a medicament to affect an immune disorder. 15 According to a thirteenth aspect of the present invention, there is provided a pharmaceutical composition comprising or prepared from an agent according to the present invention. 20 Preferably, the agent capable of modulating a glycosphingolipid associated activity is a Gb3 binding agent. Preferably the agent is a verotoxin. 25 Preferably the agent is VtxB. In a particularly preferred embodiment the agent is the wild type VtxB. In one embodiment, the agent has a pentameric structure. 30 WO 99/38530 PCT/GB99/00290 12 Preferably the agent(s) is/are non-toxic. Alternatively, preferably the agent is either a mutant of VtxB which is capable of modulating a glycosphingolipid associated activity or other equivalent proteins thereof. 5 Preferably the agent is VtxB and mutants thereof which are capable of modulating a glycosphingolipid associated activity. Preferably the glycosphingolipid is Gb3. 10 In one embodiment, the agent capable of modulating a glycosphingolipid associated activity is capable of cross-linking Gb3 receptors. Preferably VtxB is a suitable example of an agent which is capable of cross-linking 15 Gb3. Preferably good cross-linking is achieved by virtue of its pentameric form. Preferably the medicament is used for the treatment or prophylaxis of an immune 20 disorder. Preferably the medicament includes one or more antigens which are optionally co administered with the agent. 25 In one preferred embodiment, the agent is coupled to an antigen. In one preferred embodiment, the agent is uncoupled to an antigen. 30 WO 99/38530 PCT/GB99/00290 13 Preferably the agent may be administered to a mammal with or without CO administration of an antigen. Preferably the mammal is a human - e.g. a human patient. 5 In accordance with the present invention we have surprisingly found that the B subunit of E.coli verotoxin (VtxB) induces a similiar modulatory effect on CD8+ T cells to that of CtxB and EtxB. This effect is very surprising as VtxB binds to an alternative receptor (the glycolipid receptor Gb3) which is different from that utilised by EtxB and 10 CtxB and is was not expected that VtxB would induce similiar effects to that of CtxB and EtxB. In particular, we have surprisingly found that the use of agents having Gb3 associated activity, when given alone or when co-administered with suitable antigens, exert 15 immunomodulatory effects useful in the treatment of immune disorders. We have also surprisingly found that a verotoxin administered on its own and without adjuvant can serve to immunomodulate the immune system. Thus, VtxB can serve as a vaccine adjuvant which is capable of promoting the antigenicity of a protein. In 20 addition, immune disorders may be treated with an agent, such as VtxB, capable of modulating a glycosphingolipid associated activity (for example, a Gb3 associated activity) for instance, which is not coupled with an antigen. Significantly, the linkage of the components was not found to be necessary. 25 Furthermore, our findings indicate that the mechanisms of protection against immune disorders may include, though not be limited to an immunomodulation of the immune system.
WO 99/38530 PCT/GB99/00290 14 Thus, the present invention is advantageous because immune disorders can be treated with an agent capable of modulating a glycosphingolipid associated activity. The agent may be coupled or uncoupled to an antigen. 5 The term "glycosphingolipid" as used with respect to the present invention include glycosphingolipids capable of acting as receptors for VtxB or VtxB-like agents as well as active fragments thereof. For the purposes of this invention, the glycosphingolipid is not GM1. 10 The term "glycosphingolipid associated activity" includes any one or more of modulating or immunomodulating a glycosphingolipid receptor, modulating any signalling event prior to, during or subsequent to glycosphingolipid binding. The term "Vtx" refers to the verotoxin and VtxB refers to the B subunit of the vero 15 toxin. In other texts, these may sometimes be identified as VT or VTB respectively. Alternatively, the toxin can be referred to as a Shiga-like toxin (SLT) or Stx. The verotoxin can be made synthetically or isolated from natural sources. Alternatively, it can be obtained from commercial sources. 20 As used herein, "shiga-like toxin" or "SLT" refers to group of toxins produced by enterohemorrhagic E. coli that resemble the Shigella-produced shiga toxins as is commonly understood in the art. These toxins comprise an enzymatically active A subunit and a multimeric receptor binding B subunit. Such SLTs include SLTI and the various grouped toxins designated in the art SLTII. 25 The term "GM1 binding agent" includes any agent which acts as an immunomodulator through interacting with a GM1 ganglioside receptor.
WO 99/38530 PCT/GB99/00290 15 The term "Etx" herein means the E. coli heat labile enterotoxin and EtxB is the B subunit of Etx. In other texts, these may sometimes be identified as LT or Lt and LTB or LtB respectively. 5 The term "adjuvant" includes a substance that enhances an immune response to an antigen. The term "vaccine adjuvant" includes an agent which is delivered with an unrelated antigen, such that the agent is capable of facilitating an immune response to the 10 unrelated antigen. In this way, the agent acts as a so-called vaccine adjuvant. The term "vaccine adjuvant" includes the term "mucosal adjuvant". The term "mucosal adjuvant" includes an agent which is delivered mucosally with an unrelated antigen, such that the agent is capable of facilitating a mucosal immune 15 response to the unrelated antigen. In this way, the agent acts as a so-called mucosal adjuvant. A "vaccine carrier" includes a carrier of relevant antigens (Szostak et al 1996 J Biotechnol 44: 161-170) 20 The term "mucosal surfaces" includes but is not limited to oral, sublingual, nasal, vaginal, rectal, salivary, intestinal and conjunctival surfaces. The term "mucosal membrane" and/or "mucosal tissue" includes but is not limited to 25 the intestine, the lung, the mouth, the genital tract, the nose and the eye. The term "mucosal immunogen" includes an agent administerable by a mucosal route that has the capability to evoke cell mediated immune reactions and/or delayed type hypersensitivity reactions. 30 WO 99/38530 PCT/GB99/00290 16 The term "immunological or oral tolerance" means a reduction in immunological reactivity of a host towards a specific antigen(s). Immunological or oral tolerance may not mean a complete suppression of the immune response to a particular antigen but it is a form or tolerance also known as "immune deviation" or "split tolerance". 5 The term "immune deviation" or "split tolerance" can be used to describe the likely preservation of local IgA responses with the retention of some IgG responses but with the down regulation of delayed hypersensitivity and IgE responses. 10 The term "tolerance" means a state of specific immunological unresponsiveness. The term "immune disorder" includes conditions such as allergic conditions or hypersensitivity conditions, autoimmune and inflammatory diseases, cancers such as human leukaemias of a T cell origin, transplantation rejection and graft versus host 15 disease (GVHD). The term "autoimmunity" is used to describe the mechanism by which the body generates an immune response to self-antigens. 20 The term "agent capable of modulating a glycosphingolipid associated activity" can be used to describe any agent which acts as an immunomodulator through interacting with a glycosphingolipid. The term "immunomodulator" includes any agent that alters the extent of the immune 25 response to an antigen, by altering the antigenicity of the antigen or by altering in a nonspecific manner the specific reactivity or the nonspecific effector associated mechanisms of the host. The term "administered" includes delivery by viral or non-viral techniques. Viral 30 delivery mechanisms include but are not limited to adenoviral vectors, adeno-associated WO 99/38530 PCT/GB99/00290 17 viral (AAV) vectos, herpes viral vectors, retroviral vectors, lentiviral vectors, and baculoviral vectors. Non-viral delivery mechanisms include lipid mediated transfection, liposomes, immunoliposomes, lipofectin, cationic facial amphiphiles (CFAs) and combinations thereof The routes for such delivery mechanisms include but are not 5 limited to mucosal, nasal, oral, parenteral (such as intravenous (iv), intramuscular (im), or subcutaneous (sc) route), gastrointestinal, topical, or sublingual routes. The term "co-administered" means that the site and time of administration of each of the agent and the antigen are such that the necessary modulation of the immune system 10 is achieved. Thus, whilst the agent and the antigen may be administered at the same moment in time and at the same site, there may be advantages in administering the agent at a different time and to a different site from the antigen. The agent and antigen may even be delivered in the same delivery vehicle (such as a MacrosolM-see WO95/13795 and WO96/14871). 15 The term "administered" includes but is not limited to delivery by a mucosal route, for example, as a nasal spray or aerosol for inhalation or as an ingestable solution; a parenteral route where delivery is by an injectable form, such as, for example, an intravenous, intramuscular or subcutaneous route. 20 The term "systemic immunisation" means the introduction of an antigen into a non mucosal tissue such as the skin or the blood. The term "self antigens" means components derived from host tissues. 25 The term "target interaction components" includes but is not limited to an agent capable of modulating a glycosphingolipid associated activity, a glycosphingolipid and/or an antigen.
WO 99/38530 PCT/GB99/00290 18 The term "uncoupled" - which is synonymous with the term "unlinked" - means that the agent is not coupled to the antigen. The term "coupled" - which is synonymous with the term "linked" - means the linkage 5 of the agent with the antigen - which includes but is not limited to direct linkage (such as by a covalent bond) or indirect linkage such as by the provision of suitable spacer groups. However, in accordance with the present invention, the agent and/or antigen can be 10 coupled to another entity. The term "affect" includes modulation, such as treatment, prevention, suppression, alleviation, restoration or other alteration of pre-existing condition and/or to potentially affect a future condition, as well as any combination thereof. 15 An "antigen" means an agent which, when introduced into an immunocompetent animal, stimulates the production of a specific antibody or antibodies that can combine with the agent. The antigen may be a pure substance, a mixture of substance or soluble or particulate material (including cells or cell fragments). In this sense, the term 20 includes any suitable antigenic determinant, auto-antigen, self-antigen, tolerogen, allergen, hapten, and immunogen, or parts thereof, as well as any combination thereof, and these terms are used interchangeably throughout the text. A "tolerogen" means a tolerated antigen. 25 A "hapten" means a small molecule which can act as an epitope but is incapable by itself of eliciting an antibody response. Examples of antigens include but are not limited to: insulin; myelin basic protein; 30 antibody or antibody fragments; gamma globulins; transplantation antigens or cells WO 99/38530 PCT/GB99/00290 19 expressing said transplantation antigens, such as red blood cells, platelets and lymphocytes; bacterial toxins; and/or synthetic peptides and/or corresponding variants, homologues, derivatives or fragments thereof of the above mentioned antigens. 5 An "allergen" includes any antigen that stimulates an allergic reaction, inducing a Type I hypersensitivity reaction. Examples of common allergen sources are outlined in the Table below. Group Examples of Allergens Airborne grass pollens ragweed, rye, couch, wild oat, timothy, Bermuda, Kentucky blue, mugwort tree pollens alder, birch, hazel, beech, Cupressae, oak,olive moulds Aspergillus spp., Cladosporium spp., Alternaria spp., Basidospores, Ascomycetes cereal grains wheat, rye, oat animal dander and urine cat, dog, horse, rabbit, guinea pig, hamster bird feathers budgerigar, parrot, pigeon, duck, chicken house dust mite Dermatophagoides pteronyssinus, D.farinae, Euroglyphus maynei insects cockroach, fly, locust, midge WO 99/38530 PCT/GB99/00290 20 Oral Oral seafood, legumes, peanuts, nuts, cereals, dairy foods products, eggs, fruits, tomatoes, mushrooms, alcoholic beverages, coffee, chocolate drugs penicillins, sulphonamides and other antibiotics, sulphasalazine, carbamazepine Injected Injected bee and wasp stings, ant and mosquito bites insects blood products, sera, vaccines, contrast media, drugs (including anti-asthma drugs and drugs antibiotics) The term "allergic condition" includes but is not limited to asthma, allergic cough, allergic rhinitis and conjunctivitis, atopic eczema and dermatitis, uticaria, hives, insect 5 bite allergy, dietary allergy (peanut, fish milk, wheat etc) and drug allergies. The term "hypersensitivity condition" includes but is not limited to conditions such as contact hypersensitivity induced by plant poison ivy. 10 The term "agent" includes entities capable of modulating a glycosphingolipid associated activity. The agent can be one or more of an inorganic or organic chemical, as well as combinations thereof. By way of example the agent can be a polypeptide as well as a variant/homologue/derivative/fragment thereof so long as they retain the required immunomodulatory activity. It also includes mimics and equivalents and 15 mutants thereof. Other agents for the prevention and/or treatment of immune disorders include antibodies to the target interaction components. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments, fragments produced by a Fab expression library and specifically designed humanised monoclonal antibodies. 20 WO 99/38530 PCT/GB99/00290 21 Agents capable of modulating a glycosphingolipid associated activity may be designed and produced as outlined above, by methods which are known in the art. By way of example, when the agent of the invention is a protein such as the VtxB subunit it may be produced, for use in all aspects of this invention by a method in which the gene or 5 genes coding for the specific polypeptide chain (or chains) from which the protein is formed, is inserted into a suitable vector and then used to transfect a suitable host. For example, the gene coding for the polypeptide chain from which the VtxB assemble may be inserted into suitable expression vectors (such as plasmids) which are then used to transfect host cells, such as Vibrio sp.60. The protein is purified and isolated 10 in a manner known per se. Mutant genes expressing active mutant VtxB protein may then be produced by known methods from the wild type gene. In E. coli, verotoxins are encoded by one or more bacteriophages and, furthermore, individual strains may produce either one or both VT1 and VT2. Both the natural and 15 the recombinant forms of E. coli verotoxin have been isolated. One such recombinant cloned toxin is pJLB28 which expresses both the A and B subunits (Huang, A. et al (1986) J. Bacteriol. 166, 375-379). Where a target interaction component is a protein, procedures well known in the art 20 may be used for the production of antibodies to that component. For the production of antibodies, various hosts including goats, rabbits, rats, mice, etc. may be immunized by injection with the target interaction component or any derivative or homologue thereof or oligopeptide which retains immunogenic properties. 25 Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminium hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. BCG (Bacilli Calmette-Guerin) and Corynebacterium 30 parvum are potentially useful human adjuvants.
WO 99/38530 PCT/GB99/00290 22 Where a target interaction component is a protein, monoclonal antibodies to that component may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique originally described by Koehler and Milstein 5 (1975 Nature 256:495-497), the human B-cell hybridoma technique (Kosbor et al (1983) Immunol Today 4:72; Cote et al (1983) Proc Natl Acad Sci 80:2026-2030) and the EBV-hybridoma technique (Cole et al (1985) Monoclonal Antibodies and Cancer Therapy, Alan R Liss Inc, pp 77-96). In addition, techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human 10 antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used (Morrison et al (1984) Proc Natl Acad Sci 81:6851-6855; Neuberger et al (1984) Nature 312:604-608; Takeda et al (1985) Nature 314:452-454). Alternatively, techniques described for the production of single chain antibodies (US Patent No. 4,946,779) can be adapted to produce target interaction component specific 15 single chain antibodies. Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in Orlandi et al (1989, Proc Natl Acad Sci 86: 20 3833-3837), and Winter G and Milstein C (1991; Nature 349:293-299). Antibody fragments which contain specific binding sites for a target interaction components may also be generated. For example, such fragments include, but are not limited to, the F(ab') 2 fragments which can be produced by pepsin digestion of the 25 antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab') 2 fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse WD et al (1989) Science 256:1275-128 1).
WO 99/38530 PCT/GB99/00290 23 The target interaction components of the present invention or a derivative or homologue thereof and/or a cell line that expresses the target interaction components of the present invention or a derivative or homologue thereof may be used to screen for antibodies, peptides, or other agent, such as organic or inorganic molecules, that act as 5 modulators of the target interaction, thereby identifying a therapeutic agent capable of modulating the target interaction. For example, antibodies capable of modulating the target interaction may be identified. Alternatively, screening of peptide libraries or organic libraries made by combinatorial 10 chemistry with recombinantly expressed target interaction components or a derivative or homologue thereof or cell lines expressing the target interaction components or a derivative or homologue thereof may be useful for identification of therapeutic agents that function by modulating the target interaction. Synthetic compounds, natural products, and other sources of potentially biologically active materials can be screened 15 in a number of ways deemed to be routine to those of skill in the art. A target interaction component polypeptide, its immunogenic fragments or oligopeptides thereof can be used for screening therapeutic compounds in any of a variety of drug screening techniques. The polypeptide employed in such a test may be 20 free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The abolition of activity or the formation of binding complexes between the target interaction component and the agent being tested may be measured. Alternatively, phage display can be employed in the identification of candidate agents 25 which affect the target interaction components. Phage display is a protocol of molecular screening which utilises recombinant bacteriophage. The technology involves transforming bacteriophage with a gene that encodes an appropriate ligand (in this case a candidate agent) capable of reacting with 30 a target interaction component (or a derivative or homologue thereof) or the nucleotide WO 99/38530 PCT/GB99/00290 24 sequence (or a derivative or homologue thereof) encoding same. The transformed bacteriophage (which preferably is tethered to a solid support) expresses the appropriate ligand (such as the candidate agent) and displays it on their phage coat. The entity or entities (such as cells) bearing the target molecules which recognises the 5 candidate agent are isolated and amplified. The successful candidate agents are then characterised. Phage display has advantages over standard affinity ligand screening technologies. The phage surface displays the candidate agent in a three dimensional configuration, more closely resembling its naturally occuring conformation. This allows for more specific and higher affinity binding for screening purposes. 10 Accordingly, the present invention provides a method for screening a plurality of agents for specific binding affinity with the target interaction component or a derivative or homologue thereof comprising providing a plurality of agents; combining the target interaction components or a derivative or homologue thereof with each of a 15 plurality of agents for a time sufficient to allow binding under suitable conditions; and detecting binding of the target interaction components, or a derivative or homologue thereof to each of the plurality of agents, thereby identifying the agent or agents which specifically bind the target interaction components. In such an assay, the plurality of agents may be produced by combinatorial chemistry techniques known to those of skill 20 in the art. Another technique for screening provides for high throughput screening of agents having suitable binding affinity to the target interaction component polypeptides and is based upon the method described in detail in WO 84/03564. In summary, large 25 numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test agents are reacted with the target interaction component fragments and washed. A bound target interaction component is then detected - such as by appropriately adapting methods well known in the art. A purified target interaction component can also be coated directly onto plates 30 for use in the aforementioned drug screening techniques. Alternatively, non- WO 99/38530 PCT/GB99/00290 25 neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support. The present invention also provides a pharmaceutical composition comprising 5 administering a therapeutically effective amount of an agent capable of modulating a glycosphingolipid associated activity and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant. The pharmaceutical compositions may be for human or animal usage and will typically 10 comprise any one or more of a pharmaceutically acceptable diluent, carrier, excipient or adjuvant. The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as - or in addition to - the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), 15 coating agent(s), solubilising agent(s). The pharmaceutical composition may be formulated together with an appropriate antigen. 20 Alternatively, a kit may be provided comprising separate compositions for each of the therapeutic agent and the antigen. In some embodiments of the present invention, the pharmaceutical compositions will comprise one or more of: an agent that has been screened by an assay of the present 25 invention; wherein the agent is capable of modulating a glycosphingolipid associated activity. The present invention also relates to pharmaceutical compositions comprising effective amounts of antigen in admixture with a pharmaceutically acceptable diluent, carrier, 30 excipient or adjuvant (including combinations thereof).
WO 99/38530 PCT/GB99/00290 26 The present invention also provides a method of treating a mammal, such as a human patient, comprising administering to said mammal an effective amount of the pharmaceutical composition of the present invention. 5 The present invention relates to pharmaceutical compositions which may comprise all or portions of the target interaction components alone or in combination with at least one other agent, such as a stabilizing compound, and may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. 10 There may be different composition/formulation requirements dependent on the different delivery systems. The pharmaceutical composition of the present invention may be formulated to be 15 delivered by a mucosal route, for example, as a nasal spray or aerosol for inhalation or ingestable solution, or parenterally in which the composition is formulated by an injectable form, for delivery, by, for example, an intravenous, intramuscular or subcutaneous route. Alternatively, the formulation may be designed to be delivered by both routes. 20 Where the agent is to be delivered mucosally through the gastrointestinal mucosa, it is preferably stable during transit though the gastrointestinal tract; for example, it should be resistant to proteolytic degradation, stable at acid pH and resistant to the detergent effects of bile. 25 Typically, a physician will determine the actual dosage which will be most suitable for a subject and it will vary with the age, weight and response of the particular subject. While a single dose of the agent and the antigenic determinant may be satisfactory, multiple doses are contemplated within the scope of the invention. 30 WO 99/38530 PCT/GB99/00290 27 Where appropriate, the pharmaceutical compositions can be administered by inhalation, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch, orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either 5 alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intracavernosally, intravenously, intramuscularly or subcutaneously. For parenteral administration, the compositions may be best used in the form of a sterile aqueous solution which may contain other substances, for example 10 enough salts or monosaccharides to make the solution isotonic with blood. For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner. There may be different delivery requirements dependent on the different 15 composition/formulation systems. Expression vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of the agent to the targeted tissue and/or cell population. Methods which are well known to those skilled 20 in the art can be used to construct recombinant vectors containing the agent. Alternatively, the agent can be delivered to target cells in liposomes. By way of example, the controlled release of vaccine antigens on mucosal surfaces using biodegradable polymer microspheres may help to target antigens and reduce the 25 numbers of doses required for primary immunisation (Gupta and Siber 1995 Vaccine 13: 1263-1276) Encapsulation of vaccines in biodegradable microspheres provides excellent mucosal immunogens. Recombinant Norwalk Virus-like (rNV) particles may also be used for WO 99/38530 PCT/GB99/00290 28 the oral delivery of mucosal immunogens (Ball et al 1996 Arch Virol Suppl 12: 243 249) Viral Like Particles (VLPs) have been utilised as vaccine delivery system for multiple 5 immunogens including B and T cell epitopes (Roy 1996 Intervirology 39: 62-71). One preferred method of oral delivery uses formations as described in WO95/13795, WO96/17593 and WO96/17594. These formulations allow macromolecules such as proteins to be solubilised in "oils" for oral delivery. Such formulations therefore allow 10 delivery of the macromolecules to mucosal surfaces in the gut. In a further approach, again when the therapeutic agent is a protein, it is possible to deliver such proteins by means of a bacterial delivery system such as that described in WO 93/17117. This system utilises the bacterium Lactococcus lactis to deliver 15 proteins, for instance orally or indeed by other mucosol routes such as nasally. In summary, the present invention provides the use of an agent in the manufacture of a medicament to affect an immune disorder; wherein the agent is capable of modulating a glycosphingolipid associated activity. 20 In another broad aspect, the present invention provides an agent capable of modulating a glycosphingolipid associated activity and which is potently immunogenic. Other aspects of the present invention are now presented below by way of numbered 25 paragraphs, which include: 1. The use of a Gb3 binding agent, or an agent having an effect on Gb3 intracellular signalling events, but no Gb3 binding activity, in the preparation of a medicament for the treatment or prophylaxis of inflammatory conditions, autoimmune 30 diseases, transplant rejection, graft versus host disease, immune disorders or cancer.
WO 99/38530 PCT/GB99/00290 29 2. The use as claimed in paragraph 1 wherein the agent is VtxB. 3. The use as claimed in paragraph 1 or paragraph 2 wherein the medicament also comprises one or more antigens/allergens. 5 4. A pharmaceutical formulation comprising a Gb3 binding agent, or an agent having an effect on Gb3 intracellular signalling events, but no Gb3 binding activity, optionally together with one or more pharmaceutically acceptable carriers, diluents or excipients. 10 5. A pharmaceutical formulation as claimed in paragraph 4 wherein the agent is VtxB. 6. A pharmaceutical formulation as claimed in paragraph 5 which also comprises 15 one or more allergens/antigens. 7. A pharmaceutical formulation as claimed in paragraph 5 or paragraph 6 which is a vaccine formulation. 20 8. A method for the treatment or prophylaxis of an inflammatory condition, an autoimmune disease, transplant rejection, GVHD, allergic, or other hypersensitive conditions or cancer which comprises administering to a subject an effective amount of a Gb3 binding agent, or an agent having an effect on Gb3 intracellular signalling events, but no Gb3 binding activity. 25 9. A method of vaccinating a subject against, for example an immune disorder, which comprises administering to a subject an effective amount of a Gb3 binding agent, or an agent having an effect on Gb3 intracellular signalling events, but no Gb3 binding activity. 30 WO 99/38530 PCT/GB99/00290 30 10. A product comprising an agent having Gb3 binding activity, or an agent having an effect on Gb3 mediated intracellular signalling events, but no Gb3 binding activity, in the preparation of a medicament to treat an inflammatory condition, an autoimmune disease, transplant rejection, CVHD, an immune disorder or cancer, and at least one 5 antigen/allergen as a combined preparation for simultaneous, separate or sequential use. The present invention will now be further described by example in which reference is made to the following Figures: 10 Figure 1 shows the serum anti-VtxB antibody responses in NIH mice following subcutaneous immunisation with VtxB; and Figure 2 shows the upregulation in IL-2R (CD25) expression induced by binding of 15 EtxB (A), CtxB (B) and VtxB (C) to lymphocyte populations. In slightly more detail, the serum anti-VtxB antibody titre in column 1 of Figure 1 was obtained in NIH mice immunised with 10ig VtxB in complete Freund's adjuvant on day 1 and 10p[g VtxB in incomplete Freund's adjuvant on Days 8 and 15 whereas the 20 serum anti-VtxB antibody titre in column 2 was obtained in NIH mice immunised with 10pig of VtxB without complete or incomplete Freund's adjuvant on days 1, 8 and 15. Mice were bled on day 28. Antibody titres to VtxB were determined on VtxB-coated microtitre plates. 25 The upregulation of CD25 expression on CD8+ T cells induced by CtxB, EtxB and VtxB in Figure 2 is represented by increased binding of CD25 antibodies labelled with FITC and detected as a shift in the intensity of FITC fluorescence by FACs analysis The dotted lines represent levels of CD25 expression in unstimulated cells. 30 WO 99/38530 PCT/GB99/00290 31 EXAMPLES Example 1. Serum anti-VtxB antibody responses in NIH mice following subcutaneous immunisation with VtxB. 5 NIH mice were immunised (s.c.) on days 1, 8 and 15 with 10p.g of VtxB in Freund's adjuvant, 10pg of VtxB alone or PBS (control). Mice were bled on day 28. Antibody titres to VtxB were determined on VtxB-coated microtitre plates. 10 The results in Figure 1 demonstrate that the serum anti-VtxB antibody titre in NIH mice treated with VtxB without adjuvant were almost twice that seen in NIH mice treated with VtxB with adjuvant. These results indicate that (i) in the absence of adjuvant, VtxB is potently immunogenic (ii) VtxB administered on its own and without adjuvant can serve to immunomodulate the immune system and (iii) that (i) 15 and (ii) above indicate that VtxB is capable of acting as a vaccine adjuvant. Example 2. Examination of CD25 (IL-2R) cell surface expression on VtxB treated lymphocyte populations by FACS analysis. 20 NIH female mice ranging between the ages of 6 to 8 weeks were sacrificed and Mesenteric lymph node tissue was subsequently removed into Hanks balanced salt solution (HBSS without Calcium and Magnesium). Lymphocytes were then dispersed into the solution and away from fibrous tissue through gently pressing the tissue through a wire mesh. 25 Following 3 washes in HBSS, CD8+T cells were purified by separation in a magnetic MACS column. Briefly, 100 million cells were resuspended in 300pl MACS buffer (PBS/0.5% BSA/0.5mM EDTA). For positive selection 20tl of MACS anti-CD8 antibody was added to cell suspension and the mixture was incubated on ice for a 30 period of 30 minutes to allow time for effective antibody interaction.
WO 99/38530 PCT/GB99/00290 32 Following incubations cells were subsequently washed in cold MACS buffer and passed through a pre-washed VS+ selection column (MACS). The CD8 + T cells bound to the column and then eluted by the force of a plunger, washed and cultured for 20 hours at a concentration of 2 million cell/ml in the presence of either no antigen or 5 40pg/ml EtxB, VtxB or CtxB. After the period of stimulation, cells were washed and resuspended in HBSS/2% sodium azide at a concentration of 2 million/ml. Phycoerythrin (PE) conjugated anti CD8 and biotin labelled anti CD25 were incubated on ice with the cellular suspensions 10 at dilutions of 1 in 250 and 1 in 125 respectively for 45 minutes. Streptavidin conjugated FITC was then added to cell samples following a brief spin and incubated for a further 45 minutes. Following antibody incubations, cell samples were washed twice in cold HBSS 15 followed by once in ISOTON solution. Levels of FITC and PE fluorescence as a representation of CD25 and CD8 expression respectively were analysed by a FACS machine (Hewlettt Packard). The results demonstrate the surprising finding that the B subunit of E.coli verotoxin 20 (VtxB) induces a similiar modulatory effect on CD8+ T cells, in terms of upregulation of IL-2R expression, to that of CtxB and EtxB. This effect is very surprising as VtxB binds to an alternative receptor (the glycolipid receptor Gb3) which is different from that utilised by EtxB and CtxB and is was not expected that VtxB would induce similiar effects to that of CtxB and EtxB. 25 Screens for Agents capable of modulating glycosphingolipid associated activity Agents capable of modulating glycosphingolipid associated activity are tested by any one of a variety of methods. 30 WO 99/38530 PCT/GB99/00290 33 Examples of such methods include, but are not limited to the following methods: 1. Binding to a glycosphingolipid, such as Gb3, is determined by using purified Gb3 to coat microtiter plates. Following blocking of further non-specific protein binding to 5 the plate, the agent under investigation is applied to the plate and allowed to interact prior to washing and detection with specific antibodies to said agent. Conjugation of the antibodies either directly or indirectly to an enzyme or radiolabel allows subsequent quantification of binding either using colormetric or radioactivity based methods (ELISA or RIA respectively). 10 2. The pentasaccharide moiety of a glycosphingolipid, such as Gb3, is bound to a suitable column matrix in order to allow standard affinity chromatography to be performed. Removal of known compounds applied to the column from the diluent are used as evidence for binding activity. Alternatively, where mixtures of compounds are 15 applied to the column, elution and subsequent analysis allows the properties of the agent capable of modulating glycosphingolipid associated activity to be determined. Protein analysis includes peptide sequencing and tryptic digest mapping followed by comparisons with available databases. If eluted proteins cannot be identified in this 20 way, then standard biochemical analysis, such as, for example, mass determination by laser desorption mass spectrometry is used to further characterise the compound. Non proteins eluted from Gb3-affinity columns are analysed by HPLC and mass spectrometry of single homogenous peaks. 25 3. The ability to bind to glycosphingolipid, such as Gb3, and the precise affinity of the interaction may be determined using plasmon surface resonance as previously reported by (Kuziemko et al (1996) Biochem 35:6375-6384). Other screens for agents capable of activating B cells, CD4+ T cells, depleting CD8+ T 30 cells and inducing alterations in lymphocyte nuclear morphology characteristics of WO 99/38530 PCT/GB99/00290 34 cells undergoing apoptosis are outlined in WO97/02045 and are incorporated herein by reference. Evaluation of identified agents 5 The identification of agents capable of modulating a glycosphingolipid associated activity such that the modulation of the glycosphingolipid associated activity affects an autoimmune condition is determined as follows: 10 Animal models of an autoimmune disease can be used to assess the efficacy of an agent capable of modulating a glycosphingolipid associated activity to prevent autoimmune disease. An example of the use of an animal model of autoimmune disease is the induction of 15 arthritis in DBA/1 mice. Evaluation of agents is conducted by injecting groups of DBA/1 mice with bovine collagen in Complete Freund's Adjuvant (CFA) by intradermal (id) injection in the flank in the presence or absence of the agent capable of modulating a glycosphingolipid associated activity in order to assess prevention of disease development. 20 Such mice are given a second injection of collagen in Incomplete Freund's Adjuvant (IFA) in the presence/absence of the agent capable of modulating a glycosphingolipid associated activity. All animals are assessed for severity of disease on day 45 by measuring hind limb ankle thickness or scoring each hind limb digit for swelling. 25 The identification of agents capable of modulating a glycosphingolipid associated activity such that the modulation of the glycosphingolipid associated activity affects an allergic condition and/or a hypersensitivity condition is determined as follows: WO 99/38530 PCT/GB99/00290 35 Laboratory animals are stimulated to produce antigen-specific IgE by methods well known in the art. By way of example, mice are challenged with alum precipitated soluble protein antigen (e.g. ovalbumin or allergens known to be involved in human allergic diseases such as ragweed or house dust mite antigens) either subcutaneously or 5 intraperitoneally. In the unmanipulated animal, this procedure routinely leads to the production of antigen-specific IgE which is easily detected in the serum, by standard ELISAs, using the antigen to coat suitable microtiter plates. Serum from the immunised mice is 10 applied to the plates after non-specific protein binding has been blocked and the presence of IgE is determined using widely available labelled antibodies specific for murine IgE. In order to screen agents for their capability to prevent or treat allergy, agents capable 15 of modulating glycosphingolipid associated activity are administered to mice either in the presence or absence of the challenge antigen at a range of doses, and by a variety of routes. Although the oral route is the preferred method of administration, delivery can be by other mucosal surfaces or parenterally. The frequency of such administration as well as the timing of repetitive dosing is also investigated. Such intervention strategies 20 are utilised either prior to the IgE inducing antigen challenge (prophylaxis) or after the IgE inducing antigen challenge (treatment). Antigen challenge can be either with (i) the antigen used as part of the prophylactic or treatment protocol; (ii) an unrelated antigen or (iii) a mixture of the challenge and unrelated antigen in order to test the specificity of the response and the induction of bystander suppression respectively. 25 Efficacy is determined in a variety of ways and is manifested as a number of different outcomes. 1. Antigen-specific IgE levels. Measurement of serum IgE by specific ELISA (as 30 described) is used to determine whether prophylactic or treatment protocols are WO 99/38530 PCT/GB99/00290 36 capable of reducing levels of serum antigen-specific IgE. Other methods known in the art for the determination of IgE response are used either as alternatives to ELISA or in order to provide complementary data. Such methods include the so-called "Ussing Chamber test" or "passive cutaneous anaphylaxis" assay. A reduction in specific IgE, 5 as determined by any of these assays, is a strong marker of potential clinical efficacy. 2. Antigen specific T-cell reactivity. The responses of T-cells, derived from secondary lymphoid organs of the treated animals to the challenge antigen, is investigated using established methodology. Cell suspensions are prepared and 10 cultured, in the presence or absence of the challenge antigen. At appropriate time intervals after the initiation of the cultures, samples are assessed for cell proliferation and cytokine production. Cytokines are measured by specific capture ELISA, by intracellular staining followed 15 by cytometric analysis, by RT-PCR or by other established procedures. Comparison of cell proliferation and cytokine production, in the presence of antigen as opposed to its absence, provides in each case a measure of that part of the response which is specific to the challenge antigen. Evidence of efficacy of prophylactic or treatment protocols is demonstrated by a reduction in the production of Th2 associated cytokines (in 20 particular IL-4) or by an increased expression of cytokines which are involved in down-regulating the allergic response (for example, IL-10 or TGFP3). 3. IgG and IgA levels. Protocols which do not reduce the levels of antigen specific IgE can still be considered as potentially effective in the event that they are also able to 25 enhance the production of other non-allergy associated antibody isotopes. Thus investigation of serum and mucosal secretions from animals which have been either untreated or given agents under investigation as part of prophylactic or treatment protocols for the presence of IgG and IgA are also carried out. Standard antigen specific ELISA assays (as described) utilising detecting antibodies specific for IgG and 30 specific subclass thereof, and IgA are used for this purpose. Enhanced production of WO 99/38530 PCT/GB99/00290 37 secreted or serum IgG or IgA antibodies indicate efficacy since such antibodies can be expected to prevent an allergen from cross-linking IgE bound to mast cells, basophils and eosinophils or limit the uptake of antigen across the mucosal epithelium and hence prevent the subsequent allergic inflammatory response. 5 In one aspect of the present invention, a glycosphingolipid binding assay for the detection of glycosphingolipid binding agents such as verotoxins has been developed according to the teachings as set out in US5164298. This assay is based on the immobilization of deacylated globotriaosyl ceramide in microtitre wells. 10 In one preferred embodiment of this invention, deacylated Gb3 is bound to a microtitre plate for use in an ELISA for the detection of a Gb3 binding agent such as verotoxin. The verotoxin present in verotoxin containing samples, or verotoxin positive controls will bind to the deacylated Gb3 which has been bound to the plate. 15 The glycolipid-bound toxin is visualized by use of a polyclonal rabbit antiserum and an immunoperoxidase indicator system. Other indicator systems well known to those skilled in the art of ELISA would also be suitable. 20 Those skilled in the art of ELISA would also know that a deacylated Gb3, having a free amino group, could also be covalently bound to another protein either directly or through the incorporation of a spacer arm. This second protein could then be used in the primary binding step in the assay. Similarly, instead of attaching the glycosphingolipid to a protein as an assay component, it could be covalently bound 25 directly to a solid phase support as an assay component or alternatively, the assay component may be a liposome which contains the glycosphingolipid receptor. Such solid phase supports include microtitre plates, test tubes, glass beads, nitrocellulose and latex particles. The plates or test tubes may be of glass or a plastic such as polyvinyl chloride, polystyrene or latex. 30 WO 99/38530 PCT/GB99/00290 38 The principle of using a glycosphingolipid in a receptor-based assay for verotoxin could be applied to any of the well known assay technologies, including radioimmunoassay, cell-binding cytotoxicity assays, thin layer chromatography assays and agglutination assays. The principle could also be used in a fluorescence based 5 receptor assay for verotoxin using toxin sensitive target cells as the receptor bearing vehicle. Enzyme Linked Immunosorbent Assays (ELISAs) 10 Binding of VtxB to Gb3 or deacylated Gb3 can also be examined using an adaptation of the GM1 ELISA reported by Amin, T., & Hirst, T.R (1994 Prot. Express. and Purif. 5, 198-204) where GM1 is replaced by Gb3 or deacylated Gb3 respectively. Sera and gut secretions are examined for the presence of anti-B subunit IgG and IgA 15 antibodies by ELISAs in which samples are applied to microtitre plates (Immulon I, Dynateck, USA) coated with 5tg/ml of VtxB in PBS. Anti-B subunits IgA antibodies in gut secretion supernatants are extrapolated from a standard curve made by coating 2 rows of wells on each plate with l1tg/ml rabbit anti-mouse IgA (cc chain specific; Zymed Lab, USA) in PBS followed by addition of 1lg/ml of mouse myeloma IgA 20 (MOPC 315, Sigma, USA). To measure total IgA, wells are coated with rabbit anti mouse IgA followed by addition of gut secretion supernatants. All samples are serially diluted. Goat anti-mouse IgG (Fc fragment specific; Jackson Lab., USA) or goat anti mouse IgA (a chain specific; Sigma) peroxidase conjugate are diluted and added to all wells. The anti-B subunit IgG titer, giving an A 45 0nm > 0.2, is determined. The IgA 25 anti-B subunit response for the VtxB subunit in gut secretions is calculated as "IgA specific activity" [mean IgA anti-B subunit (pg/ml) /total IgA (Ptg/ml)]. A known ELISA method for measuring cytokine levels of IL-2, IL-4, IL-5, IL-10 and IFN-y is used. Briefly, microtiter plates are coated with rat antibodies to mouse IL-2, 30 IL-4, IL-5, IL-10 and IFN-y. Plates are blocked with 2% (w/v) bovine serum albumin.
WO 99/38530 PCT/GB99/00290 39 Supernatants from culture medium are added to wells and diluted down. One row on each plate for each cytokine contains a standard amount of recombinant cytokines. Plates are then incubated with 0.5 ig/ml of biotinylated anti-cytokine monoclonal antibodies followed by addition of avidine-peroxidase and 3,3', 5,5' 5 Tetramethylbenzidene (TMB) substrate and read at A 450 nm. All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the 10 scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to 15 be within the scope of the following claims.

Claims (23)

1. The use of an agent in the manufacture of a medicament to affect an immune disorder; 5 wherein the agent is capable of modulating a glycosphingolipid associated activity; and wherein the modulation of the glycosphingolipid associated activity affects an 10 immune disorder.
2. The use of an agent in the manufacture of a medicament to affect an immune disorder; 15 wherein the agent is capable of modulating a globotriaosylceramide (Gb3) associated activity; and wherein the modulation of the Gb3 associated activity affects an immune disorder. 20
3. The use of an agent according to claim 1 or claim 2 wherein the agent is capable of in vivo modulating lymphocyte populations.
4. The use of an agent according to claim 1 or claim 2 wherein the agent is also 25 capable of acting as a vaccine adjuvant.
5. The use of an agent according to claim 1 or claim 2 wherein the agent is capable of promoting the antigenicity of a protein. 30
6. An assay method for identifying an agent according to any one of claims 1 to 5 WO 99/38530 PCT/GB99/00290 41 that is capable of affecting an immune disorder; wherein the assay method comprises: 5 (a) contacting an agent with a glycosphingolipid; (b) determining whether the agent modulates a glycosphingolipid associated activity; 10 such that the modulation of the glycosphingolipid associated activity is indicative that the agent may be capable of affecting an immune disorder.
7. An assay method according to claim 6 wherein the assay is to screen for an agent useful in the prevention and/or treatment of an immune disorder. 15
8. A process comprising the steps of: (a) performing the assay according to claim 6 or claim 7; 20 (b) identifying one or more agents capable of modulating a glycosphingolipid associated activity; and (c) preparing a quantity of those one or more agents. 25
9. A process comprising the steps of: (a) performing the assay according to claim 6 or claim 7; (b) identifying one or more agents capable of modulating a glycosphingolipid 30 associated activity; and WO 99/38530 PCT/GB99/00290 42 (c) preparing a pharmaceutical composition comprising one or more identified agents.
10. A process comprising the steps of: 5 (a) performing the assay according to claim 6 or claim 7; (b) identifying one or more agents capable of modulating a glycosphingolipid associated activity; and 10 (c) modifying one or more identified agents that modulates a glycosphingolipid associated activity; and (d) preparing a pharmaceutical composition comprising those one or more modified 15 agents.
11. An agent identified by the process of claim 8 or claim 9 or claim 10.
12. An agent according to claim 11 wherein the agent is a glycosphingolipid binding 20 agent.
13. An agent according to claim 11 wherein the agent is a Gb3 binding agent.
14. An agent according to claim 13 wherein the agent is VtxB. 25
15. An agent according to claim 11 wherein the agent had not previously been known to affect an immune disorder through modulation of a glycosphingolipid associated activity. WO 99/38530 PCT/GB99/00290 43
16. An agent according to claim 11 wherein the agent had not previously been known to affect an immune disorder through modulation of a Gb3 associated activity.
17. The invention according to claims 6 to 10 wherein the glycosphingolipid is a 5 Gb3 glycosphingolipid.
18. A method of affecting an immune disorder with one or more agents; wherein the agent is capable of modulating a glycosphingolipid associated 10 activity in an in vitro assay method; and wherein the in vitro assay method is the assay method defined in claim 6 or claim 7. 15
19. Use of an agent as defined in any one of claims 6 to 18 in the manufacture of a medicament to affect an immune disorder
20. An agent according to claim 11 or claim 12 or claim 13 or claim 14 or an agent prepared by a process according to claim 8 or claim 9 or claim 10 for use as a 20 pharmaceutical.
21. A pharmaceutical composition comprising or prepared from an agent according to any one of claims 11 or claim 12 or claim 13 or claim 14 or an agent prepared by a process according to claim 8 or claim 9 or claim 10 and a pharmaceutically acceptable 25 carrier, diluent, excipient or adjuvant or any combination thereof.
22. Use of an agent in the preparation of a pharmaceutical composition wherein the agent is that defined in any one of claims 11 or claim 12 or claim 13 or claim 14 or an agent prepared by a process according to claim 8 or claim 9 or claim 10 for the 30 treatment of an immune disorder. WO 99/38530 PCT/GB99/00290 44
23. An agent capable of modulating a glycosphingolipid associated activity substantially as described herein. 5
AU22900/99A 1998-01-28 1999-01-28 Agent capable of modulating a glycosphingolipid-associated activity thus affecting an immune disorder Abandoned AU2290099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9801871 1998-01-28
GBGB9801871.6A GB9801871D0 (en) 1998-01-28 1998-01-28 Therapies
PCT/GB1999/000290 WO1999038530A1 (en) 1998-01-28 1999-01-28 Agent capable of modulating a glycosphingolipid-associated activity thus affecting an immune disorder

Publications (1)

Publication Number Publication Date
AU2290099A true AU2290099A (en) 1999-08-16

Family

ID=10826080

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22900/99A Abandoned AU2290099A (en) 1998-01-28 1999-01-28 Agent capable of modulating a glycosphingolipid-associated activity thus affecting an immune disorder

Country Status (5)

Country Link
EP (1) EP1049489A1 (en)
AU (1) AU2290099A (en)
CA (1) CA2318190A1 (en)
GB (1) GB9801871D0 (en)
WO (1) WO1999038530A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513733D0 (en) * 1995-07-05 1995-09-06 Univ Bristol Therapeutic agents
CA2163716C (en) * 1995-11-24 2009-05-19 Clifford A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
US5801145A (en) * 1996-02-09 1998-09-01 Ontario Cancer Institute Method for selectively purging CD77+ cells from bone marrow
WO1998051326A1 (en) * 1997-05-16 1998-11-19 Hsc Research And Development Limited Partnership Inhibition of angiogenesis by verotoxins

Also Published As

Publication number Publication date
CA2318190A1 (en) 1999-08-05
EP1049489A1 (en) 2000-11-08
GB9801871D0 (en) 1998-03-25
WO1999038530A1 (en) 1999-08-05

Similar Documents

Publication Publication Date Title
US8992940B2 (en) Agent for treating allergic or hypersensitivity condition
US20050147627A1 (en) Toll-like receptor 5 ligands and methods of use
US20150017202A1 (en) Synthetic toll-like receptor-4 (tlr-4) agonist peptides
US20210164991A1 (en) Induced common antibody response
KR20010052170A (en) TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES
JP2002514607A (en) Immunomodulators for vaccines
AU2290099A (en) Agent capable of modulating a glycosphingolipid-associated activity thus affecting an immune disorder
US20030007973A1 (en) Methods and compositions for manipulation of the immune response using anti-metallothionein antibody
US20020055488A1 (en) Prevention and treatment of streptococcal and staphylococcal infection
CZ2001839A3 (en) Peptide fragments of cholera toxin B or enterotoxin B as vaccine adjuvants
AU2003261492B2 (en) Vaccine
AU2006249261A1 (en) Vaccine
US20190269771A1 (en) Peptide mimotope that induces an immune response against mycobacterium tuberculosis lipoarabinomannan (lam)
JP2003517445A (en) Peptides useful for reducing the signs of toxic shock syndrome and septic shock

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted